Vijoice Granule
Product Images NDC 0078-1175

15 FDA label images from Novartis Pharmaceuticals Corporation · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Vijoice (NDC 0078-1175). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Alpelisib Structural Formula (Vijoice 01)

Alpelisib Structural Formula (Vijoice 01)
Chemical structure of alpelisib, the active ingredient in VIJOICE. The diagram shows the molecular framework including rings, functional groups, and substituents relevant to alpelisib.*
FDA Label Image

Figure A (Vijoice T 01)

Figure A (Vijoice T 01)
An illustration showing two items: a small cup containing liquid on the left, and a spoon holding a liquid drop on the right. The image appears to depict measuring or administering a liquid dose, but does not show any text or branding related to VIJOICE or alpelisib tablets.*
FDA Label Image

Figure B (Vijoice T 02)

Figure B (Vijoice T 02)
An illustration showing a hand placing a tablet into a bottle or container using a tool, demonstrating a step in medication handling or administration for oral tablets.*
FDA Label Image

Figure C (Vijoice T 03)

Figure C (Vijoice T 03)
Illustration showing three objects representing oral medication forms or dosing tools: a small cup, a syringe, and a spoon. These items are commonly used for administering oral drugs like tablets or liquids.*
FDA Label Image

Figure D (Vijoice T 04)

Figure D (Vijoice T 04)
An instructional illustration depicting a hand holding a syringe, positioned above a small container. An upward arrow indicates pulling the syringe upward from the container, suggesting a step in medication preparation or withdrawal.*
FDA Label Image

Figure A (Vijoice O 01)

Figure A (Vijoice O 01)
An illustration showing a glass of water alongside a tablet cutter or splitter tool, typically used to divide tablets into smaller doses. The image visually suggests the use of the tablet cutter when taking an oral tablet like VIJOICE (alpelisib).*
FDA Label Image

Figure B (Vijoice O 02)

Figure B (Vijoice O 02)
An instructional illustration showing a person administering an oral tablet using a small dosing applicator, accompanied by a small cup likely containing liquid for swallowing the tablet.*
FDA Label Image

Figure C (Vijoice O 03)

Figure C (Vijoice O 03)
An illustration featuring three separate images: a glass of water, a pair of scissors, and a spoon. These images likely represent common items associated with medication administration or preparation.*
FDA Label Image

Figure D (Vijoice O 04)

Figure D (Vijoice O 04)
An illustration showing a hand pouring granules or powder from a packet into a glass. A spoon is placed beside the glass, suggesting preparation or administration instructions for an oral dosage form.*
FDA Label Image

Figure E (Vijoice O 05)

Figure E (Vijoice O 05)
An instructional illustration showing three items for medication administration: a small cup, a syringe, and a spoon. The image likely relates to different methods of oral drug delivery but does not display any specific product labeling or text.*
FDA Label Image

Figure F (Vijoice O 06)

Figure F (Vijoice O 06)
An instructional illustration showing a hand holding a device with an arrow indicating upward movement. The device is positioned above a small container, suggesting a step in medication preparation or use. No text or brand identifiers are visible.*
FDA Label Image
Principal Display Panel								Vijoice®								(alpelisib) Tablets								Ndc 0078-1021-84								50 mg Daily Dose								Take One 50 mg Tablet Once Daily								Rx Only								Recommended Dosage: Take One 50 mg Tablet Once Daily With Food.								Swallow Tablets Whole. Do Not Chew, Crush, Or Split Tablets.								Directions: See Enclosed Instructions For Use For Administration								Instructions, Including Options For Patients Who Are Unable To Swallow								Whole Tablets.								28-day Supply								Contains: One Blister Pack Containing 28 Tablets								Novartis (Vijoice 02)
Packaging label for VIJOICE 50 mg tablets containing alpelisib, an oral prescription drug by Novartis Pharmaceuticals Corporation. The box indicates a 28-day supply with one blister pack of 28 tablets. The label includes dosage instructions to take one 50 mg tablet once daily, storage conditions, and contact information for more details.*
FDA Label Image
Principal Display Panel								Vijoice®								(alpelisib) Tablets								Ndc 0078-1028-84								125 mg Daily Dose								Take One 125 mg Tablet Once Daily								Rx Only								Recommended Dosage: Take One 125 mg Tablet Once Daily With Food.								Swallow Tablets Whole. Do Not Chew, Crush, Or Split Tablets.								Directions: See Enclosed Instructions For Use For Administration								Instructions, Including Options For Patients Who Are Unable To Swallow								Whole Tablets.								28-day Supply								Contains: One Blister Pack Containing 28 Tablets								Novartis (Vijoice 03)
Vijoice 125 mg tablets carton packaging label for oral use. The label shows the proprietary name Vijoice with the generic name alpelisib, indicating a 125 mg daily dose. It includes usage instructions, storage information, and contains 28 tablets in a blister pack. Manufactured by Novartis Pharmaceuticals Corporation.*
FDA Label Image
Principal Display Panel								Vijoice®								(alpelisib) Tablets								Ndc 0078-1035-02								250 mg Daily Dose								Take One 200 mg Tablet And One 50 mg Tablet Once Daily								Rx Only								Recommended Dosage: Take One 200 mg Tablet And One 50 mg								Tablet Once Daily With Food. Swallow Tablets Whole. Do Not Chew,								Crush, Or Split Tablets.								Directions: See Enclosed Instructions For Use For Administration								Instructions, Including Options For Patients Who Are Unable To								Swallow Whole Tablets.								28-day Supply (56 Tablets):								Contains: Two 14-day Blister Packs Each Containing 28 Tablets:								200 mg								14 Tablets Per Pack								50 mg								14 Tablets Per Pack								Novartis (Vijoice 04)
Packaging label for VIJOICE (alpelisib) tablets, showing a 250 mg daily dose consisting of one 200 mg tablet and one 50 mg tablet taken orally once daily. The label includes dosage instructions, storage guidelines, and package details for a 28-day supply containing 56 tablets in two 14-day blister packs. Manufactured by Novartis Pharma Stein AG and distributed by Novartis Pharmaceuticals Corporation.*
FDA Label Image

Principal Display Panel Rx Only Ndc 0078-1175-51 Vijoice® (alpelisib) Oral Granules 50 mg Daily Dose Take One 50 mg Packet Once Daily Directions: See Enclosed Instructions For Use For Administration Instructions. 28 Packets Novartis (Vijoice 05)

Principal Display Panel								Rx Only								Ndc 0078-1175-51								Vijoice®								(alpelisib) Oral Granules								50 mg Daily Dose								Take One 50 mg Packet Once Daily								Directions: See Enclosed Instructions For								Use For Administration Instructions.								28 Packets								Novartis (Vijoice 05)
VIJOICE 50 mg oral granules carton packaging label. The image shows the folded box design with branding for VIJOICE (alpelisib) by Novartis Pharmaceuticals Corporation. The label states 50 mg daily dose with 28 packets per carton. Instructions for use, storage conditions, and contact information for Novartis are included. The label highlights that each packet contains 50 mg alpelisib and is for prescription use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.